A different CEO would not have made ENTA’s compounds better.
Assuming that it was reasonable to develop NASH compounds, I'm curious what your thoughts are on if/how they could have killed that program more efficiently. (I don't have any insights on that particular program and won't have any follow-ups.) TIA